Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P53816
UPID:
PLAT3_HUMAN
Alternative names:
Adipose-specific phospholipase A2; Group XVI phospholipase A1/A2; H-rev 107 protein homolog; HRAS-like suppressor 1; HRAS-like suppressor 3; HREV107-3; Renal carcinoma antigen NY-REN-65
Alternative UPACC:
P53816; B2R7Q4; B7XAK5; Q3SYI3; Q9HDD1
Background:
Phospholipase A and acyltransferase 3, known by alternative names such as Adipose-specific phospholipase A2 and Group XVI phospholipase A1/A2, exhibits a broad spectrum of enzymatic activities. It functions in catalyzing the calcium-independent release of fatty acids and transferring fatty acyl groups, playing a crucial role in cellular lipid metabolism. This protein is also pivotal in eye lens terminal differentiation, ensuring lens transparency for light passage.
Therapeutic significance:
Understanding the role of Phospholipase A and acyltransferase 3 could open doors to potential therapeutic strategies.